There are roughly 100 to 120 individual antibiotic drugs available for human use today, depending on how you count combination products and different formulations. A broader FDA tally from 2016 identified about 310 approved anti-infective drugs total, but that number includes antifungals, antivirals, and antiparasitic medications alongside true antibiotics (drugs that fight bacteria specifically). The antibiotic slice of that pie is the largest single category, yet still smaller than most people assume given how often these drugs are prescribed.
That number becomes more useful once you understand how antibiotics are organized, what each group does, and why the pipeline for new ones is shrinking.
Major Antibiotic Classes
Rather than memorizing individual drug names, it helps to know that antibiotics fall into roughly a dozen major families. Drugs within the same family share a similar chemical structure and attack bacteria in the same way. The CDC groups outpatient antibiotics into these classes: penicillins, cephalosporins, macrolides, fluoroquinolones, tetracyclines, beta-lactams with increased activity (like amoxicillin-clavulanate), trimethoprim-sulfamethoxazole, lincosamides, urinary anti-infectives, and a catch-all “other” category.
Some classes contain just one or two drugs. Others, like the cephalosporins, span five generations of related compounds, each tweaked to cover a wider range of bacteria or to resist breakdown by bacterial defenses. Penicillins are similarly broad, ranging from the original penicillin to semi-synthetic versions designed decades later. This is why the total count shifts depending on whether you count each formulation separately or group closely related drugs together.
How Antibiotics Attack Bacteria
Every antibiotic works by interfering with something a bacterium needs to survive or reproduce. There are five main strategies, and knowing them helps explain why doctors sometimes combine drugs or switch classes when one stops working.
Breaking down the cell wall. This is the largest group. Penicillins, cephalosporins, carbapenems, and vancomycin all prevent bacteria from building or maintaining the rigid wall that holds them together. Without it, the bacterium bursts. Carbapenems are often called the broadest-acting antibiotics available, reserved for serious infections when other options fail.
Blocking protein production. Bacteria build proteins using tiny cellular machines called ribosomes, and several antibiotic classes gum up that process. Aminoglycosides and tetracyclines target one part of the ribosome, while macrolides, lincosamides, and a few others target a different part. Some of these kill bacteria outright; others simply stop them from multiplying, giving your immune system time to clear the infection.
Disrupting DNA or RNA. Fluoroquinolones prevent bacteria from copying their DNA, which stops them from dividing. Rifampin blocks the machinery that reads genetic instructions, halting the production of essential molecules. Metronidazole takes a different approach, generating toxic byproducts inside the bacterial cell that shred its DNA.
Starving bacteria of folic acid. Trimethoprim-sulfamethoxazole, one of the most commonly prescribed antibiotic combinations, blocks two steps in the pathway bacteria use to make folic acid, a vitamin they need to grow. Human cells get folic acid from food instead of making it, so this class hits bacteria without affecting your own cells.
Targeting specialized structures. A few antibiotics attack features found only in certain bacteria. Isoniazid, for example, disrupts the waxy outer coat unique to the tuberculosis bacterium, which is why it’s used almost exclusively for TB.
Why the Number Matters Less Than Variety
Having 100-plus antibiotics sounds like plenty until you realize many of them are minor variations on the same theme. If a bacterium evolves resistance to one penicillin, it often resists several others in the family. What doctors actually need is not more drugs within existing classes but genuinely new classes that attack bacteria in ways they haven’t encountered before.
In the U.S., more than 2.8 million antibiotic-resistant infections occur each year, and more than 35,000 people die as a direct result. When infections from C. diff, a gut bacterium that thrives after antibiotic use wipes out protective bacteria, are included, the toll rises to over 3 million infections and 48,000 deaths annually.
New Antibiotics in Development
The pipeline for new antibiotics is actually contracting. A 2025 WHO analysis found 90 antibacterial drugs in clinical development worldwide, down from 97 just two years earlier. Of those 90, only 15 qualify as truly innovative, meaning they use a new mechanism or belong to a new chemical class rather than modifying an existing drug.
The economics are a big part of the problem. Antibiotics are taken for days or weeks, not years like drugs for chronic conditions, and new antibiotics are often held in reserve to slow resistance, meaning they generate far less revenue. Several small companies that brought new antibiotics to market in the past decade went bankrupt shortly after approval. This has pushed many pharmaceutical companies to invest elsewhere, leaving the antibiotic pipeline thinner than it has been in decades.
What Most People Actually Encounter
Despite the total count, the average person will only encounter a handful of antibiotics in their lifetime. Outpatient prescriptions are dominated by a surprisingly short list: amoxicillin for ear and sinus infections, azithromycin for respiratory infections, doxycycline for skin infections and tick-borne illnesses, trimethoprim-sulfamethoxazole for urinary tract infections, and ciprofloxacin or levofloxacin for more stubborn infections. These five or six drugs (plus a few cephalosporins) account for the vast majority of the roughly 200 million outpatient antibiotic prescriptions written each year in the U.S.
The rest of the antibiotic arsenal sits mostly in hospitals, reserved for drug-resistant infections, surgical patients, or people with compromised immune systems. Many of the injectable-only antibiotics that pad the total count are drugs most people will never need and never hear of unless they face a serious, resistant infection.